Efficacy of intravenous immunoglobulin in Landau-Kleffner syndrome.
We administered 2 gm/kg of intravenous gamma globulin (IVIG) to each of five consecutive patients with Landau-Kleffner syndrome, over 4 days. We compared the 1-month baseline to that following IVIG using a severity score assessing speech, comprehension, behavior, seizures, and electroencephalography. There was a significant drop in this score after IVIG (P = 0.025). Two patients had a dramatic response to IVIG, with complete resolution of symptoms. This finding suggests that IVIG has at least some efficacy for the therapy of Landau-Kleffner syndrome.
Mikati
Mohamad A
MA
Epilepsy Program and Department of Pediatrics, American University of Beirut,New York, New York 10022, USA.
Saab
Raya
R
Fayad
Michel N
MN
Choueiri
Roula N
RN
D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D018887:Landau-Kleffner Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010865:Pilot Projects; D011446:Prospective Studies; D018709:Statistics, Nonparametric
D016756:Immunoglobulins, Intravenous